Comentis, Inc.

Also on record

Records under this name other than patents Comentis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 8 of 8 · Back to Comentis, Inc.

Patent	Title	Status	Expires	Confidence
US 9,434,724	Quinuclidines for modulating alpha 7 activity Formerly held Lapsed on the fee record Ended Sep 6, 2024 · From the USPTO record	Lapsed on the fee record	Ended Sep 6, 2024	From the USPTO record
US 8,114,891	4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof Formerly held Lapsed on the fee record Ended Feb 14, 2024 · From the USPTO record	Lapsed on the fee record	Ended Feb 14, 2024	From the USPTO record
US 7,504,420	Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Lapsed on the fee record Ended Mar 17, 2021 · High confidence	Lapsed on the fee record	Ended Mar 17, 2021	High confidence
US 9,242,973	Chromane Compounds Lapsed on the fee record Ended Jan 26, 2020 · High confidence	Lapsed on the fee record	Ended Jan 26, 2020	High confidence
US 8,975,415	Chromane Compounds Lapsed on the fee record Ended Mar 10, 2019 · High confidence	Lapsed on the fee record	Ended Mar 10, 2019	High confidence
US 7,659,289	Hydroxyethylene-Based Beta-Secretase Inhibitors and Use Thereof Lapsed on the fee record Ended Feb 9, 2018 · High confidence	Lapsed on the fee record	Ended Feb 9, 2018	High confidence
US 8,299,267	(3-Hydroxy-4-Amino-BUTAN-2-YL) -3- (2-Thiazol-2-YL-PYRROLIDINE-1-Carbonyl) Benzamide Derivatives and Related Compounds as Beta-Secretase Inhibitors for Treating Formerly held Lapsed on the fee record Ended Oct 30, 2016 · High confidence	Lapsed on the fee record	Ended Oct 30, 2016	High confidence
US 7,335,632	Beta-secretase inhibitors and methods of use thereof Lapsed on the fee record Ended Feb 26, 2012 · From the USPTO record	Lapsed on the fee record	Ended Feb 26, 2012	From the USPTO record